The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of ...

Designing drugs is a bit like playing with Polly Pocket. The vintage toy is a plastic clam shell that contains a multi-bedroom house, a skating rink, a disco dance floor, and other fun scenarios. Kids ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Nearly 1 in 7 adults in the United States lives with chronic kidney disease, a condition that often advances quietly until ...

The antibody drug market value is expected to reach $445 billion in the next five years, with over 160 antibodies currently licensed globally for a wide breadth of conditions, including cancer, ...

Researchers at Harvard Medical School developed a tool that uses artificial intelligence to accelerate drug discovery and development. The new technology, called PDGrapher, applies machine learning to ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

Researchers from David Baker's lab (University of Washington) have designed this antibody from scratch to neutralize a deadly toxin from C. difficile. [Ian Haydon] “Life could not exist without ...

An international team involving the Institute of Chemical Research, a joint centre of the University of Seville and the Spanish National Research Council, has developed a new technique that will ...

Drug-delivering aptamers that can precisely target leukemia stem cells with enhanced potency have been developed. Delivering anticancer drugs with specificity and potency to cancer stem cells is an ...